These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30847838)

  • 1. Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.
    Brooks A; Langer J; Tervonen T; Hemmingsen MP; Eguchi K; Bacci ED
    Diabetes Ther; 2019 Apr; 10(2):735-749. PubMed ID: 30847838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.
    Gelhorn HL; Osumili B; Brown K; Ross MM; Schulz A; Fernandez G; Boye KS
    Patient Prefer Adherence; 2023; 17():793-805. PubMed ID: 36987498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
    Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
    Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
    Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
    Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
    Gæde P; Johansen P; Tikkanen CK; Pollock RF; Hunt B; Malkin SJP
    Diabetes Ther; 2019 Aug; 10(4):1297-1317. PubMed ID: 31098942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
    Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
    Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
    Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
    Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
    Wilkinson L; Hunt B; Johansen P; Iyer NN; Dang-Tan T; Pollock RF
    Diabetes Ther; 2018 Jun; 9(3):951-961. PubMed ID: 29557057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
    Iacobellis G; Villasante Fricke AC
    J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
    Shubrook JH; Radin M; Ali SN; Chubb B; DiPietrantonio K; Collings H; Wyn R; Smith M
    Adv Ther; 2022 Sep; 39(9):4114-4130. PubMed ID: 35797004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
    Ishii H; Hansen BB; Langer J; Horio H
    Diabetes Ther; 2021 Feb; 12(2):613-623. PubMed ID: 33460016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study.
    Basile P; Guaricci AI; Piazzolla G; Volpe S; Vozza A; Benedetto M; Carella MC; Santoro D; Monitillo F; Baggiano A; Mushtaq S; Fusini L; Fazzari F; Forleo C; Ribecco N; Pontone G; Sabbà C; Ciccone MM
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.